Most Volatile Stocks to Day Trade (BZH, NKTR, SYUT, HZNP)

New York, NY -- (SBWIRE) -- 11/13/2012 -- Beazer Homes USA, Inc. (NYSE:BZH) diversified homebuilder with active operations in 16 states. In the Company’s homebuilding operations, it designs, sells and builds single-family and multi-family homes. During the fiscal year ended September 30, 2011(fiscal 2011), the Company launched its pre-owned homes division which acquires, improves and rents out recently built, previously owned homes within select markets in which the Company has homebuilding operations. Its segments include homebuilding-west, homebuilding-east and homebuilding-southeast.

Beazer Homes USA (BZH) reported a fourth quarter loss per share of $2.82 Monday morning, compared to last year's loss of $2.91. The consensus estimate was for a loss of $1.22 per share. Revenues grew to $370.93 million from $334.91 million a year ago. The consensus estimate was for revenues of $335.11 million.

Beazer Homes USA gapped open lower Monday and has fallen further in the last half hour of trade. Shares are now down 1.80 at $14.84, with volume beginning to accelerate. The stock has dropped to a 2-month low and has slipped beneath its 200-day moving average.

How Should Investors React To BZH Now? Find Out Here

Nektar Therapeutics (NASDAQ:NKTR) is a clinical-stage biopharmaceutical company developing a pipeline of drug candidates, which utilize its PEGylation and advanced polymer conjugate technology platforms. As of December 31, 2011, its pipeline was consisted of drug candidates across a range of therapeutic areas, including oncology, pain, anti-infectives, anti-viral and immunology. Its research and development activities involve small molecule drugs, peptides and other potential biologic drug candidates.Shares of Nektar Therapeuti (NASDAQ:NKTR) are trading at $7.04 and is -28.88% from its 50-day Moving Average price of $9.8982 and -17.39% from its 200-day Moving Average price of $8.5221. The average trading volume is 1100270 shares and its market capitalization is $810.8M.

Should A Trader Buy Or Sell NKTR Now: CHECK HERE

Synutra International Inc (NASDAQ:SYUT) announced that for fiscal 2013, it expects revenue in the range of approximately $300-$350 million and a net loss of approximately $30-$50 million. The Company also announced that revenue growth in the fiscal second half is expected to be greater than the first half. According to I/B/E/S Estimates, analysts are expecting the Company to report revenue of $388 million and Net Income of $43 million for fiscal 2013; revenue of $141 million in the third quarter of 2013; revenue of $125 million for the fourth quarter of 2013.

How Should Investors Trade SYUT Now? Check Here

Horizon Pharma, Inc. (NASDAQ:HZNP) announced an additional analysis of data from the pivotal Circadian Administration of Prednisone in Rheumatoid Arthritis-2 or CAPRA-2 clinical trial demonstrating that patients with active rheumatoid arthritis or RA treated with its recently approved RAYOS 5 mg (prednisone) delayed-release tablets had a significant improvement in reduction of fatigue, as determined by the Functional Assessment of Chronic Illness Therapy - Fatigue or FACIT-F questionnaire. Horizon Pharma Inc (NASDAQ:HZNP) shares climbed 7.51% to $2.29. The company announced that its third quarter 2012 financial results will be released on Tuesday, November 13, 2012. Following the announcement, Horizon’s management will host a live conference call and webcast at 8:00 am Eastern Time to review the Company’s financial and operating results and provide a general business update.

Can HZNP Find The Bottom? Find Out Here

DISCLAIMER
Neither PennyStocksUpdate.biz nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor or broker dealer in any jurisdiction whatsoever and none of the information provided by PennyStocksUpdate.biz, owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or an investment recommendation.PennyStocksUpdate.biz makes no recommendation that the securities of the companies profiled should be purchased, sold or held by individuals or entities that learn of the profiled companies through PennyStocksUpdate.biz. Investing in securities is speculative and carries a high degree of risk and no investment should be made unless you can afford to lose your entire investment. It is possible that an investor's entire investment may be lost or impaired due to the speculative nature of the companies profiled. Please consult a broker before purchasing or selling any securities viewed on or mentioned here in..

Contact:
PennyStocksUpdate.biz
info@pennystocksupdate.biz